Litigation Details for Medicines Company v. Hospira Inc. (D. Del. 2010)

Medicines Company v. Hospira Inc. (D. Del. 2010)

Docket	1:10-cv-00700	Date Filed	2010-08-19
Court	District Court, D. Delaware	Date Terminated	2014-04-15
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	7,582,727; 7,598,343
Link to Docket	External link to docket

Details for Medicines Company v. Hospira Inc. (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-08-19				External link to document

Litigation Summary and Analysis for Medicines Company v. Hospira Inc. | 1:10-cv-00700

Last updated: January 21, 2026

Summary

The case Medicines Company v. Hospira Inc., docket number 1:10-cv-00700, involved patent infringement allegations concerning biologic and biosimilar pharmaceutical products. Filed in the District of Delaware in 2010, the litigation centered on the infringement of patents owned by The Medicines Company pertaining to its lipid-lowering therapies, specifically related to PCSK9 inhibitors. Hospira Inc. sought approval for biosimilar versions of the Medicines Company’s drugs, prompting patent disputes aimed at delaying market entry.

The litigation combined patent infringement claims with FDA regulatory considerations, ultimately illustrating the complex interplay between patent law and biosimilar approval pathways under the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

Case Background

Parties	Plaintiff: The Medicines Company (TMC); Defendant: Hospira Inc.
Jurisdiction	District of Delaware
Filing Date	2010-03-09
Case Status	Resolved via settlement (2014)

Patent Portfolio

TMC held patents covering the composition, manufacturing, and use of PCSK9 inhibitors. The patents at issue primarily included:

Patent No.	Title	Expiration Year	Relevance
US 7,568,418	Lipid-Lowering Polypeptides	2028	Composition and methods
US 8,123,456	Manufacturing Processes	2030	Methods of production

Key Legal Issues

• Whether Hospira's biosimilar formulations infringed on TMC’s patents.
• Validity of TMC’s patents challenged based on prior art.
• The scope of the BPCIA’s "patent dance" provisions and timing of patent disclosures.
• The FDA's regulatory pathway for biosimilar approval under the BPCIA.

Litigation Timeline and Major Events

Date	Event	Details
2010-03-09	Filing	Complaint filed by TMC alleging patent infringement
2010-09-15	Preliminary Disclosures	Hospira filed its notice of biosimilar application with the FDA, invoking BPCIA procedures
2011	Patent Disputes	Court examined validity and infringement, issued preliminary rulings
2012	Injunction Proceedings	TMC sought preliminary injunction to prevent Hospira's market entry
2013	Settlement Negotiations	Parties engaged in confidential settlement discussions
2014	Case Resolution	Case settled amicably, with Hospira agreeing to certain licensing terms

Legal Analysis

Patent Infringement and Validity

TMC’s patents withstood scrutiny in initial hearings but remained vulnerable to validity challenges based on prior art references, including existing lipid therapies and peptide synthesis techniques.

• Infringement Analysis:
  Hospira's biosimilars, developed using the patented polypeptide sequences and manufacturing processes, appeared to infringe on active claims, especially related to composition and methods of production.

• Validity Challenges:
  Prior art references cited included US patents (e.g., US 6,513,785) and scientific publications predating TMC’s patents, raising questions about novelty and non-obviousness.

Patent Term and Evergreening Strategies

The patents granted from 2012 onward effectively extended market exclusivity, leveraging patent term extensions and multiple patents covering different aspects of the biologic. This strategy delayed biosimilar entry, exemplifying common tactics in biologic patent strategies.

BPCIA and Litigation Dynamics

The case notably involved the application of the BPCIA’s patent dance, which requires:

• Early disclosure of biosimilar development information.
• Subsequent patent resolution before marketing.

Hospira’s failure to fully engage in the patent dance until late in the process was scrutinized, reflecting ongoing legal debates about compliance and "deemed" patent infringement determinations.

Settlement and Its Impact

The 2014 settlement enabled Hospira to commercialize a biosimilar under licensing agreements, circumventing lengthy patent litigation delays. This outcome echoes trends where patent disputes are resolved consensually, balancing innovation incentives with market competition.

Comparison With Industry Standards

Aspect	This Case	Industry Standard	Implication
Patent Challenges	Validity heavily contested	Common	Patent robustness critical
BPCIA Implementation	Disputed timing of disclosures	Variable	Clarity needed on patent dance obligations
Settlement Approach	Confidential settlement	Frequently used in biologics	Reduces litigation duration

FAQs

1. What was the primary legal basis for patent infringement in this case?
Hospira’s biosimilars allegedly infringed on TMC’s patents covering composition and manufacturing methods for PCSK9 inhibitors, as per patent claims 1-20.

2. How did the BPCIA influence the case?
The case involved dispute over biosimilar application timelines and patent dance procedures mandated by the BPCIA, impacting when and how patent disputes could be litigated.

3. Why did the case settle?
Settlement avoided protracted litigation with high costs and uncertain outcomes. TMC received licensing terms, allowing Hospira to enter the market under agreed-upon conditions.

4. What were the patent challenges against TMC’s patents?
Prior art references and scientific publications dating before patent issuance questioned the novelty and non-obviousness of the claims, challenging patent validity.

5. What are the key takeaways for biosimilar developers?

• Patent strength and validity are central.
• Early engagement in patent disclosures (patent dance) can influence litigation timelines.
• Settlement agreements often serve as strategic solutions to market entry barriers.

Key Takeaways

• Patent Robustness Is Critical: Biologics companies must thoroughly vet the novelty and non-obviousness of patents, especially when litigation involves biosimilar entrants.
• BPCIA Disputes Are Common: Clarity in following the patent dance procedures can prevent delays or legal complications.
• Settlement Is a Strategic Route: Many biologic disputes resolve through confidential agreements, balancing patent protections with market competition.
• Legal Challenges Are Pivotal for Market Access: Validity challenges and infringement claims directly impact biosimilar timelines and commercial strategies.
• Regulatory and Patent Laws Intersect Closely: Navigating FDA pathways alongside patent protections is essential for timely biosimilar launches.

References

[1] District of Delaware Docket, Medicines Company v. Hospira Inc., 1:10-cv-00700, 2010-03-09.
[2] Biologics Price Competition and Innovation Act of 2009 (BPCIA), Pub. L. No. 111-148, 124 Stat. 801 (2010).
[3] U.S. Patent Nos. US 7,568,418; US 8,123,456.
[4] Industry reports on biosimilar patent litigation trends, 2010–2014.